Travere Therapeutics, Inc. (TVTX) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGM. Market cap 4.84B USD. 52-week range 22.59 to 68.73 USD. Data as of 2026-10-09.
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport ...